iRhythm Holdings, Inc.

iRhythm Holdings, Inc. is a digital healthcare company that designs, develops, and commercializes device-based technology for ambulatory cardiac monitoring services. Its primary offering is the Zio platform, which includes several prescription-only remote electrocardiogram (ECG) monitoring systems. The Zio XT System and Zio Monitor System use a patch that continuously records the heart's electrical signal for up to 14 days. The Zio AT System adds a wireless gateway for connectivity during the wear period. iRhythm also provides long-term and short-term continuous monitoring and mobile cardiac telemetry services. The company's technology helps diagnose arrhythmias by capturing and analyzing ECG data through its Zio ECG Utilization Software System. Additionally, iRhythm has a development collaboration with BioIS to integrate pulse oximetry, accelerometry, and non-invasive blood pressure technologies into its products.

iRhythm Holdings, Inc. is publicly traded on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IRTC. Its shares are denominated in US Dollars (USD), reflecting its primary listing in the United States. The company's stock is traded on this major US exchange, providing liquidity and visibility to investors. As a US-based company, all financial reporting and transactions are conducted in USD.

iRhythm Holdings, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it focuses on digital health solutions for cardiac monitoring. Its products are classified as prescription-only remote ECG monitoring systems, which are regulated medical devices. The company's work sits at the intersection of healthcare technology and traditional medical devices, leveraging digital tools to improve arrhythmia diagnosis. This industry involves rigorous regulatory oversight and clinical validation, and iRhythm's offerings are used by healthcare providers to monitor patients with suspected or known cardiac rhythm disorders.

iRhythm Holdings, Inc. is headquartered in the United States and primarily serves the US market. According to its description, the company provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. While it may have global aspirations, its current operations and commercialization efforts are focused domestically. The company was incorporated in 2006 and formerly known as iRhythm Technologies, Inc. before rebranding. Its US-centric focus allows it to navigate the specific regulatory and reimbursement landscape of the American healthcare system.

iRhythm's main products are part of the Zio family of ambulatory cardiac monitoring systems. The Zio XT System is a prescription-only remote ECG monitoring system that uses a patch to record heart signals continuously for up to 14 days. The Zio AT System adds a wireless gateway for real-time connectivity during the wear period. The Zio Monitor System is another prescription-only option for continuous monitoring. All these systems are supported by the Zio ECG Utilization Software System, which captures and analyzes ECG data. Additionally, iRhythm offers long-term and short-term continuous monitoring and mobile cardiac telemetry services. The company is also collaborating with BioIS to develop pulse oximetry, accelerometry, and non-invasive blood pressure technologies for integration into future products.